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Abstract
Purpose During the COVID-19 pandemic, there have been particular concerns regarding the related impact on specialist
tumour services. Neuroendocrine tumour (NET) services are delivered in a highly specialised setting, typically delivered in a
small number of centres that fulfil specific criteria as defined by the European Neuroendocrine Tumour Society (ENETS).
We aimed to address the COVID-19-related impact on specialist NET tumour services in England and other countries.
Methods Electronic survey addressing patient access and delivery of care distributed to all ENETS Centres of Excellence
(CoE) in England and matching number of ENETS CoE elsewhere. Semi-quantitative and qualitative analyses of survey
responses were performed.
Results Survey response of ENETS CoE in England was 55% (6/11). Responses from six non-UK ENETS CoE elsewhere
were received and analysed in a similar manner. Relevant disruption of various NET services was noted across all
responding Centres, which included delayed patient appointments and investigations, reduced availability of treatment
modalities including delayed surgical treatment and a major negative impact on research activities. The comparison between
English and non-UK ENETS CoE suggested that the former had significantly greater concerns related to future research
funding (p= 0.014), whilst having less disruption to multidisciplinary meetings (p= 0.01). A trend was also noted towards
virtual patient appointments in ENETS CoE in England vs. elsewhere (p= 0.092).
Conclusions Restoration of highly specialised NET services following COVID-19 and planning for future service delivery
and research funding must take account of the severe challenges encountered during the pandemic.
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Introduction
COVID-19 was first described amongst a cluster of patients
suffering from pneumonia in Wuhan, China [1]. Fuelled by
its viral novelty, high infectivity and global mobility [2],
COVID-19 rapidly spread around the world, and within just
3 months became a global pandemic. As a rapidly evolving
and dynamic entity, the true global implications of COVID-
19 remain unknown, and will probably only become clear in
many years to come. As per 12th of November 2020, at
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least 1.27 million people have died from COVID-19. The
tsunami-like ramifications of COVID-19 and the associated
need for ‘lockdown’ and ‘social distancing’ have had a
devastating impact on the global economy that is unprece-
dented in the modern era [3].
COVID-19 has also had a unique and devastating impact
on global healthcare infrastructures and administration, with
multiple contributing factors. Although there are inevitable
direct effects on service provision from increased hospital
including intensive care admissions of patients with
COVID-19, it is perhaps the multiple and insidious indirect
effects of the COVID-19 pandemic that have most affected
healthcare. During the COVID-19 era, there has been a
dramatic reduction in the usage of NHS-based services
[4, 5], potential explanations including patient-based risk
perceptions and the impact of government-based messages
regarding lockdown and self-isolation [5]. Coupled with this
has been healthcare staff redeployment in many hospitals to
manage the surge in hospital admissions with COVID-19,
coupled with re-purposing of clinical areas for COVID-19
screening, with an associated and inevitable disruption to the
provision of non-COVID-19 based, but nonetheless essential
healthcare. To address these multiple and complex factors,
much healthcare provision has been administered through
remote media, such as phone calls and telehealth [6]. The
versatility and convenience of such remote healthcare pro-
vision promotes its likely ongoing usage for at least some
aspects of service in the post-COVID-19 era.
Of particular concern has been the impact of COVID-19 on
tumour services, including the impact of delayed and missed
clinic appointments for the overall health of the populace
[7, 8]. Healthcare provision for neuroendocrine tumours
(NETs) represents a specialised form of services that is typi-
cally administered by highly skilled multidisciplinary teams
operating within s Centres of Excellence (CoE). Recently,
guidance for the management of patients with NETs during
the COVID-19 era was published [9–11]. Given the nature of
NET-based clinical services, the relatively small number of
NET-based clinical centres and the vulnerability of many
patients with NETs, it is important to explore the impact of the
COVID-19 pandemic on patients with NETs, and the asso-
ciated specialist provision of healthcare.
Our aim was to perform an assessment on the impact of
COVID-19 on healthcare administration and care for patients
with NETs, with cross-national comparisons between Eur-
opean Neuroendocrine Tumour Society (ENETS) CoE based
in England and those in other countries.
Materials and methods
An electronic survey was distributed to all 11 ENETS CoE
in England, via e-mail. A similar number of non-UK
ENETS CoE were contacted, for comparison. The survey
was designed using Google Forms and captured information
in the following categories: (1) background/pre-COVID-
19 state, (2) impact of COVID-19 on clinical services, (3)
impact on operational service provision, (4) impact on
research. Questions included in the survey comprised both
semi-quantitative and qualitative response options. Quali-
tative analysis took the form of thematic analysis (and
where appropriate, coding) of answers received. A full
breakdown of the questions asked is shown in Appendix 1.
The survey was analysed comparing ENETS CoE in Eng-
land to ENETS CoE elsewhere, using both qualitative and
semi-quantitative analysis approaches including qualitative
analysis of free-text responses. Responses were received
from the specialist NET healthcare professionals (Con-
sultants/Centre leads) who consented to participate in this
survey. Given that this was an international survey, ethics
approval was pursued through the Institution with the
shortest period of approval (Ethics Committee of the Laiko
General Hospital, Athens, Greece; protocol number 10712,
date of issue 6 July 2020).
Statistical analyses
Data are presented as means ± standard error, or percen-
tages, as appropriate. Significance was defined as p < 0.05.
One-way analysis of variance was used to compare study
subgroups. Analyses were performed using SPSS version
25 (SPSS Inc., Chicago, IL).
Results
Responses received
Responses received are shown in Table 1. There were 6
(55%) of responses from the 11 ENETS CoE in England.
Responses from six ENETS CoE outside the UK were
received and used for comparison. Two additional large
specialist NET Centres in the USA and Italy were
Table 1 Responses received from contacted European Neuroendocrine
Tumour Society (ENETS) Centres of Excellence (CoE)
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contacted, but these were excluded from the analyses based
on the fact that these were not ENETS CoE, with possibly
varying practices related to the management of patients with
NET based on ENETS guidelines. We have not included a
copy of the original data to preserve anonymity of the
responses as providing such data may inadvertently allow a
specific centre to be identified.
Impact of COVID-19 in all responding ENETS CoE, all
responding centres combined (n= 6 ENETS CoE in
England and n= 6 ENETS CoE in other countries)
Impact on waiting times
The majority of ENETS CoE (58.3%, seven centres) reported
an increase in waiting times for new patients with NET, of
those 25% (three centres) reported an increase in waiting times
of >1 week, 16.7% (two centres) reported an increase in
waiting times > 2 weeks, and 16.7% (two centres) reported an
increase in waiting times > 1 month. Delays in follow-up for
patients with NET were reported in almost all responding
centres (11 centres, 91.7%), of those 4 centres (33.3%)
reported delays < 1 month, 5 centres (41.7%) reported delays
> 1 month, and 2 centres (16.7%) reported delays > 2 months.
Interestingly, one of the ENETS CoE in England (8.3%)
reported improved follow-up waiting times; however, the total
number of patients with NET in this centre was relatively
small (n= 150) when compared to typical numbers in other
ENETS CoE (n= 487 ± 200 patients in all centres combined;
n= 647 ± 384 patients in the centres in England; and 327 ±
133 patients in non-UK Centres).
Impact on diagnostic services
All of the surveyed ENETS CoE (12 centres, 100%)
reported delays on Endoscopy services, of those 1 centre
(8.3%) reported delays < 1 month, 4 centres (33.3%)
reported delays > 1 month, 6 centres (50%) reported delays
> 2 months, and 1 centre (8.3%) reported that Endoscopy
services were on halt. Only one centre (8.3%) reported that
there was no impact on morphological imaging, whereas
two centres (16.7%) reported delays < 1 month, four centres
reported delays > 1 month, and five centres reported delays
> 2 months. Delays on blood test monitoring for patients
with NET during COVID-19 were reported by 83.3% of the
centres, of those four centres (33.3%) reported small delays
< 1 month, three centres reported large delays > 1 month,
and three centres reported very large delays > 2 months.
Impact on treatment
Impact on the provision of specialist medication such as self-
administered somatostatin analogues, mTOR inhibitors or
telotristat etiprate was reported by four centres (33.3%), but in
all cases the delay was reported as small (<2 weeks). However,
as many as six ENETS CoE (50% of the surveyed centres)
reported difficulties in the availability of specific medications
such as chemotherapy and interventional radiological treat-
ment (i.e., transarterial embolization or radiofrequency abla-
tion). A negative impact on surgical treatment was reported by
11 centres (91.7%), of those 8 centres (66.7%) reported large
delays > 1 month and 3 centres (25%) reported very large
delays > 2 months. Impact on the provision of peptide receptor
radionuclide therapy (PRRT) was reported by ten of the cen-
tres (83.3%), of those four centres (33.3%) reported small
delays < 1 month, three centres (25%) reported large delays >
1 month, two centres reported very large delays > 2 months,
and one centre (8.3%) reported that PRRT was on halt. Only
two of the centres (16.7%) reported that there was no dis-
ruption to the provision of PRRT.
Change of face-to-face to virtual appointments
All 12 centres (100%) reported a move from face-to-face to
virtual appointments, of those 2 centres (16.7%) reported
that the minority of appointments were changed to virtual, 9
centres (75%) reported that the majority of appointments
were changed, and 1 of the centres (8.3%) reported that all
appointments were changed to virtual appointments. The
qualitative responses regarding clinician perceptions to
remote consultations were diverse (Table 2).
Redeployment of staff
Nursing staff was redeployed in ten centres (83.3%), of
those five centres (41.7%) reported that the minority of
nursing staff was redeployed, four centres (33.3%) reported
major nursing staff redeployment and one centre (8.3%)
reported that all nursing staff was redeployed.
Table 2 Thematic analysis of clinician perceptions regarding remote/
virtual consultations





Inability to clinically examine patients 2
Disadvantageous to patients if already
visiting for bloods, etc.
1
Can’t understand feelings/needs of patient 1
Trial recruitment is more difficult 1
Fewer patients missing appointments
(DNA’s)
1
Advantageous as reduced travel need for
patients
1
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Redeployment of medical staff (doctors) was reported by
all 12 centres (100%), of those 8 centres (66.7%) reported
minor redeployment, 3 centres (25%) reported that the
majority of medical staff was redeployed and 1 centre
(8.3%) reported that all medical staff was redeployed.
Impact on NET tumour board meetings
A negative impact on the frequency of NET tumour board
meetings was reported by four of the centres (33.3%),
whereas eight of the centres (66.7%) reported no change. A
move to virtual meetings was reported by five of the sur-
veyed centres (41.7%).
Impact on research and research funding
Only one of the centres (8.3%) reported that there was no
impact of the COVID-19 pandemic on research activity.
Some reduction in research activity was reported by four
centres (33.3%), while six of the centres (50%) reported
very significant reduction in research activity and one centre
(8.3%) reported that all research activity was stopped.
The perceived impact of the COVID-19 pandemic on the
availability of future research funding for the NET service
in the respective centres was reported as no impact by four
of the centres (33.3%), an expected small reduction in
research funding availability by two of the centres (16.7%),
a large reduction by four of the centres (33.3%) and a very
large reduction by two of the centres (16.7%).
Qualitative themes raised in relation to long-term chan-
ges to NET services included: fewer face-to-face appoint-
ments, longer waiting times, long-term impacts on treatment
and reductions in the number of staff.
Comparison of ENETS CoE in England vs. ENETS CoE
in other countries
When comparing the effects of the COVID-19 pandemic on
the responding six ENETS CoE in England vs. six ENETS
CoE in other countries, statistically significant differences
were observed related to the frequency of tumour board
meetings (p= 0.01), with none of the ENETS CoE in
England reporting a decrease in the frequency of tumour
board meetings, whereas four of the ENETS CoE elsewhere
(66.7%) reported a decrease in the frequency of tumour
board meetings. Delay in surgical treatment or treatment
with PRRT was observed in most of the participating
ENETS CoE, with no significant differences between
ENETS CoE in England and elsewhere (p= 0.33 (surgical
treatment) and p= 0.66 (PRRT), respectively).
Analysis of the perception of the impact of the pandemic
on the availability of future research funding showed that all
the surveyed six centres in England (100%) expected a
reduction in funding, of those two centres (33.3%) a small
reduction, two centres (33.3%) a large reduction and two
centres (33.3%) a very large reduction in available NET-
related research funding. In comparison, only two of the
ENETS CoE elsewhere (33.3%) expected a large reduction
in research funding availability, whereas four of the non-
England ENETS CoE expected no impact of the COVID-19
pandemic on NET research funding availability (p= 0.014).
No other significant differences were observed when com-
paring ENETS CoE in England vs. ENETS CoE elsewhere.
Related to a move from face-to-face to virtual patient
appointments, this practice tended to be more frequent in
ENETS CoE in England as compared with ENETS CoE in
other countries (p= 0.092).
Discussion
Our study is capturing ‘real life’ perceptions about the impact
of the current COVID-19 pandemic on specialist NET services
in ENETS CoE. In contrast to other recently published studies
that had also included ‘low-activity’ (<100 neuroendocrine
neoplasms (NEN) patients in follow-up) [12, 13] and ‘mid-
activity’ centres (100–300 NEN patients in follow-up) [13], in
our study we have exclusively focussed on the effects of the
COVID-19 pandemic in typically ‘high activity’, University or
University Teaching Hospital-based ENETS CoE. Our present
findings demonstrate a significant disruption to NET services
across all surveyed centres. Of note, this major disruption in
specialist NET services included relevantly increased waiting
times for both new and follow-up appointments, with an
especially substantial delay of follow-up appointments in most
of the surveyed centres. Similar findings were reported by a
recent study in Italian NEN centres [13] including also ‘low-’
and ‘mid-activity’ centres, whereas in a recent study in Ger-
many, Austria and Switzerland disruption in outpatient
appointments was more severe in the University setting as
compared with non-university hospitals and private practice
settings [12]. We also observed a relevant disruption to diag-
nostic services. Similarly, specialised treatment of patients
with NETs was delayed, which included a relevant delay in
surgical treatment; and again, in agreement with the observa-
tions made in other countries such as Italy [13]. In our survey,
this included all types of NET, independent of the primary
location and histological grading. Although many NETs are
relatively slow growing, a delay in curative surgical treatment
may result in disease spreading and clearly has the potential to
increase anxiety levels in these patients, thereby further
negatively impacting their quality of life [14].
A COVID-19 pandemic-related delay in treatment with
PRRT based on concerns, i.e., due to the frequently
observed PRRT-associated lymphopenia may be somewhat
overcautious, given that PRRT mainly appears to cause
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B-cell repletion (in 18–52% of patients treated with
177Lutetium-PRRT and some 75% of patients treated with
90Yttrium-PRRT) [15, 16], but appears to have less severe
effects on T cells and only minor effects on natural killer
cells, explaining the absence of opportunistic infections
following treatment with PRRT [15]. However, both for
planned surgical interventions and treatment with PRRT,
hospital beds need to be ‘ring-fenced’, which can be pro-
blematic in times of a pandemic with overflowing Acute
Medicine and A&E departments and the need to isolate
numerous patients in one bed rooms.
Moreover, we observed a change in practice in the way
of both new patient and follow-up appointments are pro-
vided, with all surveyed centres now providing more virtual
appointments and most centres reporting that the majority of
appointments had been converted to virtual appointments.
This change in practice was more frequently reported in the
ENETS CoE in England vs. other countries, possibly related
to the availability and fast set-up of the required equipment.
Feedback of clinicians to this change was mixed, with the
main disadvantages mentioned being unable to physically
examine the patients. However, perceived positive aspects
included improved convenience for (stable) patients who do
not live locally, and a reduced number of non-attenders.
Redeployment of both nursing and medical staff was
reported in most of the surveyed centres, but the impact on the
management of patients with NET was generally considered to
be relatively minor. A reduction in the frequency of multi-
disciplinary meetings was reported in two thirds of the ENETS
CoE outside England, but no such effect was reported in the
ENETS CoE in England. However, across the surveyed cen-
tres nearly half of the centres now run their tumour board
meetings virtually. The feedback of clinicians to this change
was generally positive, although there can be barriers related to
connection issues and the quality of the available equipment.
All but one of the non-UK centres reported that there was
a negative impact of the COVID-19 pandemic on research
activity. There was no difference in the disruption of
research activity when comparing ENETS CoE in England
vs. ENETS CoE elsewhere. However, the perceived impact
of the COVID-19 pandemic on the availability of future
research funding for the NET services in the respective
centres was bleaker in the English ENETS CoE and sig-
nificantly different between ENETS CoE in England and
elsewhere. Our results suggest that ENETS CoE in England
may face a longer road to restoration of NET services due to
reduced research activity and particularly pessimistic pre-
dictions regarding future research funding. The impact on
research funding is further important as it may coincide with
greater funding difficulties related to the UK’s departure
from the European Union (Brexit) [17–19], suggesting that
very significant efforts and mitigations would be required
UK NET research centres now, to ensure that they can fully
contribute to research in the future.
A limitation of our survey is that the data presented here,
albeit novel and detailed, is from a small sample size of
specialised ENETS CoE. Also, reporting bias cannot be
excluded, i.e., some of the NET Centres worst affected by
the COVID-19 pandemic may simply not have prioritised
responding to our survey invitation. Finally, the fact that
only one centre response for each of the other countries was
received (also having in mind that in some of the contacted
countries, only one ENETS CoE has been certified to date) is
limiting how much one can interpret the data for individual
countries other than England. The results should be inter-
preted in that context. However, despite these limitations, we
believe there are important messages for both restoration of
services and planning of future NET care and research
approaches. Overall, it is important that such specialist areas
are not being neglected in comparison to broader services.
There is important further work that is needed to monitor
and track the recovery of all services including NET services
and research following the COVID-19 pandemic. Further-
more, it is important to assess the impact of COVID-19 and
the related healthcare disruptions to services on patients
themselves, both by capturing their perceptions of care
during the pandemic and by monitoring for any worsening
outcomes that may have occurred. One of the possible
positives that appears to come from the pandemic is an
exploration of the use of virtual and remote services.
To conclude, we report on the first study to assess the
impact of COVID-19 on ENETS CoEs in England, and
compare with data from a selection of ENETS CoEs from
other western European countries. This survey has identi-
fied various deficiencies in the provision of NET services
even in highly specialised set-up, as a result of the COVID-
19 pandemic. The same may apply for tumour services in
general, although it is possible that highly specialised ser-
vices with relatively low numbers of patients could be
particularly affected. Future assessment of the impact of
COVID-19 on NET healthcare from a patient perspective is
important. Based on our data, it is important to develop
novel and unified approaches to future healthcare provision
for patients with NETs. This may include critical review of
possible widespread adoption of remote appointments and
proper planning for future pandemic scenarios that mini-
mises disruption to the provision of healthcare to this
important and vulnerable group of patients with unique and
highly specialised medical needs.
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